Minerva Neurosciences | NERV - Gross Profit On Sales


Minerva Neurosciences reported -4.27M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Adma Biologics USD 75.63M 8.4M Sep/2025
ALKERMES USD 338.34M 72.51M Dec/2025
AstraZeneca USD 12.39B 5M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 202.74M Dec/2024
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Cipla INR 41.64B 6.31B Dec/2025
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 241K 649K Sep/2025
CSL USD 4.46B 2.71B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Grifols EUR 766.49M 39.74M Dec/2024
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
J&J USD 16.6B 118M Dec/2025
Merck USD 13.42B 431M Sep/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novartis USD 10.82B 695M Sep/2025
Novavax USD 23.89M 239.21M Sep/2024
Pfizer USD 3.54B 7.61B Sep/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Takeda JPY 790.55B 262.97B Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024